Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury
Year: 2022
Type: article
Study design: Observational Study
Abstract: Background Few studies have described associations between the AKI biomarkers urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) with AKI in cisplatin-treated children. We aimed to describe excretion patterns of urine NGAL and KIM-1 and associations with AKI in children receiving cisplatin. Methods Participants ( n =159) were enrolled between 2013 and 2017 in a prospective cohort study conducted in 12 Canadian pediatric hospitals. Participants were evaluated at early cisplatin infusions (at first or second cisplatin cycle) and late cisplatin infusions (last or second-to-last cycle). Urine NGAL and KIM-1 were measured ( 1 ) pre-cisplatin infusion, ( 2 ) post-infusion (morning after), and ( 3 ) at hospital discharge at early and late cisplatin infusions. Primary outcome: AKI defined by serum creatinine rise within 10 days post-cisplatin, on the basis of Kidney Disease Improving Global Outcomes guidelines criteria (stage 1 or higher). Results Of 159 children, 156 (median [interquartile range (IQR)] age: 5.8 [2.4–12.0] years; 78 [50%] female) had biomarker data available at early cisplatin infusions and 127 had data at late infusions. Forty six of the 156 (29%) and 22 of the 127 (17%) children developed AKI within 10 days of cisplatin administration after early and late infusions, respectively. Urine NGAL and KIM-1 concentrations were significantly higher in patients with versus without AKI (near hospital discharge of late cisplatin infusion, median [IQR] NGAL levels were 76.1 [10.0–232.7] versus 14.9 [5.4–29.7] ng/mg creatinine; KIM-1 levels were 4415 [2083–9077] versus 1049 [358–3326] pg/mg creatinine; P <0.01). These markers modestly discriminated for AKI (area under receiver operating characteristic curve [AUC-ROC] range: NGAL, 0.56–0.72; KIM-1, 0.48–0.75). Biomarker concentrations were higher and better discriminated for AKI at late cisplatin infusions (AUC-ROC range, 0.54–0.75) versus early infusions (AUC-ROC range, 0.48–0.65). Conclusions Urine NGAL and KIM-1 were modest at discriminating for cisplatin-associated AKI. Further research is needed to determine clinical utility and applicability of these markers and associations with late kidney outcomes.
Source: Kidney360
Authors: Kelly R. McMahon, Hayton Chui, Shahrad Rod Rassekh, Kirk R. Schultz, Tom D. Blydt-Hansen, Cherry Mammen, Maury Pinsk, Geoffrey D. E. Cuvelier, Bruce C. Carleton, Ross T. Tsuyuki, Colin J.D. Ross, Prasad Devarajan, Louis Huynh, Mariya Yordanova, Frédérik Crépeau-Hubert, Stella Wang, Vedran Cockovski, Ana Palijan, Michael Zappitelli
Institutions: Montreal Children's Hospital, McGill University Health Centre, Research Institute of the McGill University Health Centre, McGill University, McMaster University, University of British Columbia, BC Children's Hospital, University of Manitoba, CancerCare Manitoba, BC Children's Hospital Research Institute, University of Alberta, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Queen's University, Université de Sherbrooke, University of Toronto, Hospital for Sick Children
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: diamond
Award: G676478792
OpenAlex ID: W3211264458
